Ridgetech, Inc. - Ordinary Shares (RDGT)

Watching the tape on RDGT, the market sentiment is deeply skeptical despite the reported 10.2% YoY revenue growth to $132.2M for fiscal year 2026. When a micro-cap trades down over 99% year-to-date and sits at a $1.11M market cap, traditional valuation metrics like a P/E of 0.00 completely break down. The overriding market focus is on survival and execution rather than fundamental multiples.

On our desk, the sheer scale of the new $184.7 million ATM program relative to their current market cap is staggering. With only about 3.63 million shares outstanding prior to the Form F-3 supplement, selling up to $184.7M in ordinary shares via Pacific Century Securities implies catastrophic dilution that could push share counts past 153 million assuming current sub-$1.25 pricing. We are advising extreme caution regarding toxic dilution mechanics.

From a restructuring and operational lens, Frank Zhao acting as interim CEO and CFO while pushing through the Allright acquisition and divesting the retail drugstore business shows a hard pivot toward a wholesale-focused pharmaceutical model in China. Candidates or analysts evaluating the firm need to examine whether this wholesale platform can generate genuine operating leverage or if it's merely a shell for ongoing capital raises.

Risk management perspective: The prior ATM sales agreement with AC Sunshine Securities was terminated and sales were temporarily suspended in July 2026 before immediately pivoting to Pacific Century Securities with a 3.5% commission structure. This rapid succession of funding vehicles highlights an urgent, burning need for liquidity beneath their Cayman Islands holding structure operating in the PRC.

Evaluating the underlying supply chain and distribution network of pharmaceutical products in Hangzhou, China requires looking closely at their recent integration of Allright. Operational questions should center on how working capital is managed across these wholesale channels given the immense cash burn and reliance on continuous equity issuances.